- Home
- RARE vs SON Comparison
RARE vs SON Comparison
Compare RARE & SON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- SON
- Stock Information
- Founded
- RARE 2010
- SON 1899
- Country
- RARE United States
- SON United States
- Employees
- RARE N/A
- SON N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- SON Containers/Packaging
- Sector
- RARE Health Care
- SON Consumer Discretionary
- Exchange
- RARE Nasdaq
- SON Nasdaq
- Market Cap
- RARE 5.2B
- SON 5.1B
- IPO Year
- RARE 2014
- SON N/A
- Fundamental
- Price
- RARE $40.89
- SON $49.24
- Analyst Decision
- RARE Strong Buy
- SON Buy
- Analyst Count
- RARE 15
- SON 6
- Target Price
- RARE $92.00
- SON $60.17
- AVG Volume (30 Days)
- RARE 1.0M
- SON 759.9K
- Earning Date
- RARE 02-13-2025
- SON 02-12-2025
- Dividend Yield
- RARE N/A
- SON 4.25%
- EPS Growth
- RARE N/A
- SON N/A
- EPS
- RARE N/A
- SON 2.91
- Revenue
- RARE $522,745,000.00
- SON $6,572,688,000.00
- Revenue This Year
- RARE $26.70
- SON N/A
- Revenue Next Year
- RARE $19.02
- SON $16.95
- P/E Ratio
- RARE N/A
- SON $16.79
- Revenue Growth
- RARE 27.44
- SON N/A
- 52 Week Low
- RARE $37.02
- SON $45.93
- 52 Week High
- RARE $60.37
- SON $61.73
- Technical
- Relative Strength Index (RSI)
- RARE 40.43
- SON 54.09
- Support Level
- RARE $39.99
- SON $46.89
- Resistance Level
- RARE $44.52
- SON $47.95
- Average True Range (ATR)
- RARE 2.18
- SON 0.94
- MACD
- RARE -0.03
- SON 0.20
- Stochastic Oscillator
- RARE 17.75
- SON 97.78
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About SON Sonoco Products Company
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.